Designed for convenient daily use, these fast-absorbing oral drops support appetite regulation, satiety, and healthy metabolic function without the need for injections.* GLP-1/GIP therapy works by supporting pathways involved in appetite control, digestion, insulin response, and energy balance
Clinical Results and Safety Phase 2 clinical trials have reported encouraging weight loss outcomes, with participants receiving the highest doses achieving an average body weight reduction of approximately 24% over 48 weeks
The magnitude varies significantly between individuals: STEP 4 Trial : Participants who stopped semaglutide after 20 weeks regained approximately 7% body weight over next 48 weeks (compared to losing an additional 8% who continued medication) Real-World Studies : Variable outcomes
Keep exploring Explore all guides topics
It feels like you have control of your life. Before, Morales was on a constant seesaw of overeating and then starving herself
1 2 "Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 26-29 January 2026"
